[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fHGBkew76sUvwe1CJAFZK7_sieSrcimvB3ubIenOCk_s":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":34,"rows":41},"University of Regensburg",[4],69,false,7,5,7187,0,52,[14,17,19,22,25,27,29,31],{"name":15,"count":16},"Depression",9,{"name":18,"count":16},"Chronic Tinnitus",{"name":20,"count":21},"Tinnitus",6,{"name":23,"count":24},"Hepatocellular Carcinoma",2,{"name":26,"count":24},"Postoperative Residual Curarization",{"name":28,"count":24},"Colorectal Cancer Metastatic",{"name":30,"count":24},"Schizophrenia",{"name":32,"count":24},"Peritoneal Carcinomatosis",[],[35,36,37,38,39,40],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[42,69,95,113,140,168,186,217,235,253,280,298,336,358,380,402,427,452,478,503,529,554,579,602,629],{"intervention":43,"totalTrials":44,"cells":45},"Quetiapine",1,{"EARLY_PHASE1":46,"PHASE1":48,"PHASE2":50,"PHASE3":52,"PHASE4":54,"NA":67},{"trials":47,"activeCount":11},[],{"trials":49,"activeCount":11},[],{"trials":51,"activeCount":11},[],{"trials":53,"activeCount":11},[],{"trials":55,"activeCount":11},[56],{"nctId":57,"briefTitle":58,"status":59,"phases":60,"primaryCompletion":61,"completion":62,"start":63,"enrollment":64,"conditions":65,"interventions":66},"NCT00554658","Quetiapine Induced Neuroplasticity in First-episode Schizophrenic Patients","COMPLETED",[39],"2010-12","2011-03","2008-03",30,[30],[43],{"trials":68,"activeCount":11},[],{"intervention":70,"totalTrials":44,"cells":71},"CNI, MMF, Steroids, Aza etc.",{"EARLY_PHASE1":72,"PHASE1":74,"PHASE2":76,"PHASE3":78,"PHASE4":91,"NA":93},{"trials":73,"activeCount":11},[],{"trials":75,"activeCount":11},[],{"trials":77,"activeCount":11},[],{"trials":79,"activeCount":11},[80],{"nctId":81,"briefTitle":82,"status":59,"phases":83,"primaryCompletion":84,"completion":85,"start":86,"enrollment":87,"conditions":88,"interventions":89},"NCT00355862","Immunosuppression in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma",[38],"2009-04","2014-05","2006-01",525,[23],[70,90],"Sirolimus",{"trials":92,"activeCount":11},[],{"trials":94,"activeCount":11},[],{"intervention":90,"totalTrials":44,"cells":96},{"EARLY_PHASE1":97,"PHASE1":99,"PHASE2":101,"PHASE3":103,"PHASE4":109,"NA":111},{"trials":98,"activeCount":11},[],{"trials":100,"activeCount":11},[],{"trials":102,"activeCount":11},[],{"trials":104,"activeCount":11},[105],{"nctId":81,"briefTitle":82,"status":59,"phases":106,"primaryCompletion":84,"completion":85,"start":86,"enrollment":87,"conditions":107,"interventions":108},[38],[23],[70,90],{"trials":110,"activeCount":11},[],{"trials":112,"activeCount":11},[],{"intervention":114,"totalTrials":44,"cells":115},"anti-CD 25 mAb, Sirolimus, MMF",{"EARLY_PHASE1":116,"PHASE1":118,"PHASE2":120,"PHASE3":122,"PHASE4":136,"NA":138},{"trials":117,"activeCount":11},[],{"trials":119,"activeCount":11},[],{"trials":121,"activeCount":11},[],{"trials":123,"activeCount":11},[124],{"nctId":125,"briefTitle":126,"status":59,"phases":127,"primaryCompletion":128,"completion":129,"start":130,"enrollment":131,"conditions":132,"interventions":135},"NCT00604357","CNI-free de Novo Protocol in Patients Undergoing Liver Transplantation With Renal Impairment",[38],"2011-07","2012-08","2008-12",27,[133,134],"End Stage Liver Disease","Impaired Renal Function",[114],{"trials":137,"activeCount":11},[],{"trials":139,"activeCount":11},[],{"intervention":141,"totalTrials":44,"cells":142},"Etoricoxib",{"EARLY_PHASE1":143,"PHASE1":145,"PHASE2":147,"PHASE3":149,"PHASE4":164,"NA":166},{"trials":144,"activeCount":11},[],{"trials":146,"activeCount":11},[],{"trials":148,"activeCount":11},[],{"trials":150,"activeCount":11},[151],{"nctId":152,"briefTitle":153,"status":59,"phases":154,"primaryCompletion":155,"completion":155,"start":156,"enrollment":157,"conditions":158,"interventions":162},"NCT01229774","Use of Etoricoxib Compared to Diclofenac in the Perioperative Treatment of Patients After Total Hip Arthroplasty",[38],"2014-08","2011-02",100,[159,160,161],"Coxarthrosis","Arthroplasties Hip Replacement","Perioperative Blood Loss",[141,163],"Diclofenac",{"trials":165,"activeCount":11},[],{"trials":167,"activeCount":11},[],{"intervention":163,"totalTrials":44,"cells":169},{"EARLY_PHASE1":170,"PHASE1":172,"PHASE2":174,"PHASE3":176,"PHASE4":182,"NA":184},{"trials":171,"activeCount":11},[],{"trials":173,"activeCount":11},[],{"trials":175,"activeCount":11},[],{"trials":177,"activeCount":11},[178],{"nctId":152,"briefTitle":153,"status":59,"phases":179,"primaryCompletion":155,"completion":155,"start":156,"enrollment":157,"conditions":180,"interventions":181},[38],[159,160,161],[141,163],{"trials":183,"activeCount":11},[],{"trials":185,"activeCount":11},[],{"intervention":187,"totalTrials":44,"cells":188},"delayed, low-dose CNI",{"EARLY_PHASE1":189,"PHASE1":191,"PHASE2":193,"PHASE3":195,"PHASE4":213,"NA":215},{"trials":190,"activeCount":11},[],{"trials":192,"activeCount":11},[],{"trials":194,"activeCount":11},[],{"trials":196,"activeCount":11},[197],{"nctId":198,"briefTitle":199,"status":200,"phases":201,"primaryCompletion":202,"completion":203,"start":204,"enrollment":205,"conditions":206,"interventions":210},"NCT01023542","CNI-free \"Bottom\"-up Immunosuppression in Patients Undergoing Liver Transplantation","UNKNOWN",[37,38],"2014-07","2014-12","2011-06",45,[207,208,209],"Renal Impairment","Liver Transplantation","Everolimus",[187,211,212],"BU-CNI","BU-Everolimus",{"trials":214,"activeCount":11},[],{"trials":216,"activeCount":11},[],{"intervention":211,"totalTrials":44,"cells":218},{"EARLY_PHASE1":219,"PHASE1":221,"PHASE2":223,"PHASE3":225,"PHASE4":231,"NA":233},{"trials":220,"activeCount":11},[],{"trials":222,"activeCount":11},[],{"trials":224,"activeCount":11},[],{"trials":226,"activeCount":11},[227],{"nctId":198,"briefTitle":199,"status":200,"phases":228,"primaryCompletion":202,"completion":203,"start":204,"enrollment":205,"conditions":229,"interventions":230},[37,38],[207,208,209],[187,211,212],{"trials":232,"activeCount":11},[],{"trials":234,"activeCount":11},[],{"intervention":212,"totalTrials":44,"cells":236},{"EARLY_PHASE1":237,"PHASE1":239,"PHASE2":241,"PHASE3":243,"PHASE4":249,"NA":251},{"trials":238,"activeCount":11},[],{"trials":240,"activeCount":11},[],{"trials":242,"activeCount":11},[],{"trials":244,"activeCount":11},[245],{"nctId":198,"briefTitle":199,"status":200,"phases":246,"primaryCompletion":202,"completion":203,"start":204,"enrollment":205,"conditions":247,"interventions":248},[37,38],[207,208,209],[187,211,212],{"trials":250,"activeCount":11},[],{"trials":252,"activeCount":11},[],{"intervention":254,"totalTrials":44,"cells":255},"Administration of placebo",{"EARLY_PHASE1":256,"PHASE1":258,"PHASE2":260,"PHASE3":262,"PHASE4":276,"NA":278},{"trials":257,"activeCount":11},[],{"trials":259,"activeCount":11},[],{"trials":261,"activeCount":11},[],{"trials":263,"activeCount":11},[264],{"nctId":265,"briefTitle":266,"status":200,"phases":267,"primaryCompletion":268,"completion":269,"start":270,"enrollment":271,"conditions":272,"interventions":274},"NCT00756873","Etoricoxib in Ear Nose Throat Surgery",[38],"2009-09","2009-12","2008-10",90,[273],"Tonsillectomy",[254,275,275],"Administration of etoricoxib",{"trials":277,"activeCount":11},[],{"trials":279,"activeCount":11},[],{"intervention":275,"totalTrials":44,"cells":281},{"EARLY_PHASE1":282,"PHASE1":284,"PHASE2":286,"PHASE3":288,"PHASE4":294,"NA":296},{"trials":283,"activeCount":11},[],{"trials":285,"activeCount":11},[],{"trials":287,"activeCount":11},[],{"trials":289,"activeCount":11},[290],{"nctId":265,"briefTitle":266,"status":200,"phases":291,"primaryCompletion":268,"completion":269,"start":270,"enrollment":271,"conditions":292,"interventions":293},[38],[273],[254,275,275],{"trials":295,"activeCount":11},[],{"trials":297,"activeCount":11},[],{"intervention":299,"totalTrials":24,"cells":300},"Dasatinib",{"EARLY_PHASE1":301,"PHASE1":303,"PHASE2":305,"PHASE3":330,"PHASE4":332,"NA":334},{"trials":302,"activeCount":11},[],{"trials":304,"activeCount":11},[],{"trials":306,"activeCount":11},[307,320],{"nctId":308,"briefTitle":309,"status":59,"phases":310,"primaryCompletion":311,"completion":311,"start":312,"enrollment":313,"conditions":314,"interventions":316},"NCT01467986","Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma",[37],"2020-09-30","2013-08",130,[315],"Neuroblastoma Recurrent",[299,317,318,319,318,319],"Rapamycin","Irinotecan","Temozolomide",{"nctId":321,"briefTitle":322,"status":59,"phases":323,"primaryCompletion":324,"completion":324,"start":325,"enrollment":326,"conditions":327,"interventions":329},"NCT02596828","Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade Pineoblastoma",[37],"2021-04","2016-04",4,[328],"Pineoblastoma",[319,318,299,317],{"trials":331,"activeCount":11},[],{"trials":333,"activeCount":11},[],{"trials":335,"activeCount":11},[],{"intervention":317,"totalTrials":24,"cells":337},{"EARLY_PHASE1":338,"PHASE1":340,"PHASE2":342,"PHASE3":352,"PHASE4":354,"NA":356},{"trials":339,"activeCount":11},[],{"trials":341,"activeCount":11},[],{"trials":343,"activeCount":11},[344,348],{"nctId":308,"briefTitle":309,"status":59,"phases":345,"primaryCompletion":311,"completion":311,"start":312,"enrollment":313,"conditions":346,"interventions":347},[37],[315],[299,317,318,319,318,319],{"nctId":321,"briefTitle":322,"status":59,"phases":349,"primaryCompletion":324,"completion":324,"start":325,"enrollment":326,"conditions":350,"interventions":351},[37],[328],[319,318,299,317],{"trials":353,"activeCount":11},[],{"trials":355,"activeCount":11},[],{"trials":357,"activeCount":11},[],{"intervention":318,"totalTrials":24,"cells":359},{"EARLY_PHASE1":360,"PHASE1":362,"PHASE2":364,"PHASE3":374,"PHASE4":376,"NA":378},{"trials":361,"activeCount":11},[],{"trials":363,"activeCount":11},[],{"trials":365,"activeCount":11},[366,370],{"nctId":308,"briefTitle":309,"status":59,"phases":367,"primaryCompletion":311,"completion":311,"start":312,"enrollment":313,"conditions":368,"interventions":369},[37],[315],[299,317,318,319,318,319],{"nctId":321,"briefTitle":322,"status":59,"phases":371,"primaryCompletion":324,"completion":324,"start":325,"enrollment":326,"conditions":372,"interventions":373},[37],[328],[319,318,299,317],{"trials":375,"activeCount":11},[],{"trials":377,"activeCount":11},[],{"trials":379,"activeCount":11},[],{"intervention":319,"totalTrials":24,"cells":381},{"EARLY_PHASE1":382,"PHASE1":384,"PHASE2":386,"PHASE3":396,"PHASE4":398,"NA":400},{"trials":383,"activeCount":11},[],{"trials":385,"activeCount":11},[],{"trials":387,"activeCount":11},[388,392],{"nctId":308,"briefTitle":309,"status":59,"phases":389,"primaryCompletion":311,"completion":311,"start":312,"enrollment":313,"conditions":390,"interventions":391},[37],[315],[299,317,318,319,318,319],{"nctId":321,"briefTitle":322,"status":59,"phases":393,"primaryCompletion":324,"completion":324,"start":325,"enrollment":326,"conditions":394,"interventions":395},[37],[328],[319,318,299,317],{"trials":397,"activeCount":11},[],{"trials":399,"activeCount":11},[],{"trials":401,"activeCount":11},[],{"intervention":403,"totalTrials":44,"cells":404},"maintenance chemotherapy",{"EARLY_PHASE1":405,"PHASE1":407,"PHASE2":409,"PHASE3":421,"PHASE4":423,"NA":425},{"trials":406,"activeCount":11},[],{"trials":408,"activeCount":11},[],{"trials":410,"activeCount":11},[411],{"nctId":412,"briefTitle":413,"status":59,"phases":414,"primaryCompletion":415,"completion":415,"start":416,"enrollment":417,"conditions":418,"interventions":420},"NCT01614132","Multicenter Pilot-study for the Therapy of Medulloblastoma of Adults",[36,37],"2018-10","2009-01",33,[419],"Medulloblastoma",[403],{"trials":422,"activeCount":11},[],{"trials":424,"activeCount":11},[],{"trials":426,"activeCount":11},[],{"intervention":428,"totalTrials":44,"cells":429},"Pegylated Liposomal Doxorubicine",{"EARLY_PHASE1":430,"PHASE1":432,"PHASE2":434,"PHASE3":446,"PHASE4":448,"NA":450},{"trials":431,"activeCount":11},[],{"trials":433,"activeCount":11},[],{"trials":435,"activeCount":11},[436],{"nctId":437,"briefTitle":438,"status":59,"phases":439,"primaryCompletion":440,"completion":440,"start":441,"enrollment":442,"conditions":443,"interventions":445},"NCT00944801","Pegylated Liposomal Doxorubicine and Prolonged Temozolomide in Addition to Radiotherapy in Newly Diagnosed Glioblastoma",[36,37],"2009-05","2002-07",63,[444],"Glioblastoma",[428],{"trials":447,"activeCount":11},[],{"trials":449,"activeCount":11},[],{"trials":451,"activeCount":11},[],{"intervention":453,"totalTrials":44,"cells":454},"Donor M reg",{"EARLY_PHASE1":455,"PHASE1":457,"PHASE2":459,"PHASE3":472,"PHASE4":474,"NA":476},{"trials":456,"activeCount":11},[],{"trials":458,"activeCount":11},[],{"trials":460,"activeCount":11},[461],{"nctId":462,"briefTitle":463,"status":464,"phases":465,"primaryCompletion":466,"completion":466,"start":467,"enrollment":468,"conditions":469,"interventions":471},"NCT02085629","The ONE Study M Reg Trial","TERMINATED",[36,37],"2018-12-03","2014-07-24",8,[470],"Renal Failure, End Stage",[453],{"trials":473,"activeCount":11},[],{"trials":475,"activeCount":11},[],{"trials":477,"activeCount":11},[],{"intervention":479,"totalTrials":44,"cells":480},"Bevacizumab",{"EARLY_PHASE1":481,"PHASE1":483,"PHASE2":485,"PHASE3":497,"PHASE4":499,"NA":501},{"trials":482,"activeCount":11},[],{"trials":484,"activeCount":11},[],{"trials":486,"activeCount":11},[487],{"nctId":488,"briefTitle":489,"status":490,"phases":491,"primaryCompletion":492,"completion":492,"start":493,"enrollment":11,"conditions":494,"interventions":496},"NCT01540435","Perioperative Treatment of Resectable Liver Metastases","WITHDRAWN",[37],"2013-05","2012-09",[495],"Colon Cancer Liver Metastasis",[479],{"trials":498,"activeCount":11},[],{"trials":500,"activeCount":11},[],{"trials":502,"activeCount":11},[],{"intervention":504,"totalTrials":44,"cells":505},"Lenalidomide, Pioglitazone, dexamethasone, treosulfan",{"EARLY_PHASE1":506,"PHASE1":508,"PHASE2":510,"PHASE3":523,"PHASE4":525,"NA":527},{"trials":507,"activeCount":11},[],{"trials":509,"activeCount":11},[],{"trials":511,"activeCount":11},[512],{"nctId":513,"briefTitle":514,"status":200,"phases":515,"primaryCompletion":516,"completion":517,"start":518,"enrollment":519,"conditions":520,"interventions":522},"NCT01010243","Third-line Therapy of Multiple Myeloma a Prospective Phase I \u002FII Trial",[36,37],"2013-10","2016-10","2009-10",54,[521],"Multiple Myeloma",[504],{"trials":524,"activeCount":11},[],{"trials":526,"activeCount":11},[],{"trials":528,"activeCount":11},[],{"intervention":530,"totalTrials":44,"cells":531},"HIPEC",{"EARLY_PHASE1":532,"PHASE1":534,"PHASE2":536,"PHASE3":548,"PHASE4":550,"NA":552},{"trials":533,"activeCount":11},[],{"trials":535,"activeCount":11},[],{"trials":537,"activeCount":11},[538],{"nctId":539,"briefTitle":540,"status":464,"phases":541,"primaryCompletion":542,"completion":543,"start":544,"enrollment":545,"conditions":546,"interventions":547},"NCT01540344","Combined Anticancer Treatment of Advanced Colon Cancer",[37],"2015-09","2017-10","2010-10",26,[32,28],[530],{"trials":549,"activeCount":11},[],{"trials":551,"activeCount":11},[],{"trials":553,"activeCount":11},[],{"intervention":555,"totalTrials":44,"cells":556},"dacarbazine (DTIC), Trofosfamide, Etoricoxib, Pioglitazone, Temsirolimus",{"EARLY_PHASE1":557,"PHASE1":559,"PHASE2":561,"PHASE3":573,"PHASE4":575,"NA":577},{"trials":558,"activeCount":11},[],{"trials":560,"activeCount":11},[],{"trials":562,"activeCount":11},[563],{"nctId":564,"briefTitle":565,"status":200,"phases":566,"primaryCompletion":85,"completion":567,"start":568,"enrollment":569,"conditions":570,"interventions":572},"NCT01614301","Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial in Patients With Advanced Melanoma",[36,37],"2016-05","2012-05",136,[571],"Advanced Melanoma",[555],{"trials":574,"activeCount":11},[],{"trials":576,"activeCount":11},[],{"trials":578,"activeCount":11},[],{"intervention":580,"totalTrials":44,"cells":581},"Surgery with and without the aid of Indocyanine Green",{"EARLY_PHASE1":582,"PHASE1":584,"PHASE2":586,"PHASE3":588,"PHASE4":590,"NA":592},{"trials":583,"activeCount":11},[],{"trials":585,"activeCount":11},[],{"trials":587,"activeCount":11},[],{"trials":589,"activeCount":11},[],{"trials":591,"activeCount":11},[],{"trials":593,"activeCount":11},[594],{"nctId":595,"briefTitle":596,"status":59,"phases":597,"enrollment":598,"conditions":599,"interventions":601},"NCT00376857","Surgical Removal of Idiopathic Epiretinal Membrane With and Without the Assistance of Indocyanine Green.",[40],60,[600],"Idiopathic Epiretinal Membrane, Cataract",[580],{"intervention":603,"totalTrials":44,"cells":604},"Crystalloid Solutions",{"EARLY_PHASE1":605,"PHASE1":607,"PHASE2":609,"PHASE3":611,"PHASE4":613,"NA":615},{"trials":606,"activeCount":11},[],{"trials":608,"activeCount":11},[],{"trials":610,"activeCount":11},[],{"trials":612,"activeCount":11},[],{"trials":614,"activeCount":11},[],{"trials":616,"activeCount":11},[617],{"nctId":618,"briefTitle":619,"status":200,"phases":620,"primaryCompletion":621,"completion":621,"start":622,"enrollment":157,"conditions":623,"interventions":627},"NCT03118024","Perioperative Management of DIEP Flaps",[40],"2019-03","2017-03-13",[624,625,626],"Mammaplasty","Microsurgery","Free Tissue Flaps",[603,628],"Catecholamines",{"intervention":628,"totalTrials":44,"cells":630},{"EARLY_PHASE1":631,"PHASE1":633,"PHASE2":635,"PHASE3":637,"PHASE4":639,"NA":641},{"trials":632,"activeCount":11},[],{"trials":634,"activeCount":11},[],{"trials":636,"activeCount":11},[],{"trials":638,"activeCount":11},[],{"trials":640,"activeCount":11},[],{"trials":642,"activeCount":11},[643],{"nctId":618,"briefTitle":619,"status":200,"phases":644,"primaryCompletion":621,"completion":621,"start":622,"enrollment":157,"conditions":645,"interventions":646},[40],[624,625,626],[603,628]]